Toggle Nav
mobile icon
My Cart
Close
  • Menu
  • Setting
  • Home
  • Signaling Pathways

Signaling Pathways

8 Items

per page
  1. Regorafenib
    A8236 Regorafenib
     4 Citation
    Target: Raf|VEGFR|PDGFR|c-Kit|RET
    Summary: Inhibitor of VEGFR/PDGFR/FGFR/mutant kit/RET/Raf-1
      ≥25.04 mg/mL
  2. Sorafenib Tosylate
    A8245 Sorafenib Tosylate
     1 Citation
    Target: Raf|VEGFR
    Summary: Raf kinases and tyrosine kinases inhibitor
      ≥31.85 mg/mL
  3. GDC-0879
    A5071 GDC-0879
     1 Citation
    Target: Raf
    Summary: B-Raf inhibitor,potent and selective
      insoluble in EtOH; insoluble in H2O; ≥16.7 mg/mL
  4. LY3009120
    A8716 LY3009120
    Target: Raf
    Summary: pan-RAF and RAF dimer inhibitor
      insoluble in H2O; insoluble in EtOH; ≥4.25 mg/mL
  5. Vemurafenib (PLX4032, RG7204)
    A3004 Vemurafenib (PLX4032, RG7204)
     9 Citation
    Target: Raf
    Summary: BRAF kinase inhibitor
      ≥24.5 mg/mL
  6. Sorafenib
    A3009 Sorafenib
     2 Citation
    Target: Raf|VEGFR
    Summary: Raf kinases and tyrosine kinases inhibitor
      ≥23.25 mg/mL
  7. PLX-4720
    A3016 PLX-4720
     1 Citation
    Target: Raf
    Summary: BRAF kinase inhibitor
      ≥20.69 mg/mL
  8. Dabrafenib Mesylate (GSK-2118436)
    A3347 Dabrafenib Mesylate (GSK-2118436)
    Target: Raf
    Summary: Inhibitor of BRAF(V600) mutants
      ≥30.75 mg/mL

8 Items

per page